Interactive group art therapy as an adjunctive treatment for people with schizophrenia

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Crawford MJ, Killaspy H, Barnes TR, Barrett B, Byford S, Clayton K, Dinsmore J, Floyd S, Hoadley A, Johnson T, Kalaitzaki E, King M, Leurent B, Maratos A, O'Neill FA, Osborn DP, Patterson S, Soteriou T, Tyrer P, Waller D, MATISSE project team.

2012-02-2856 citations

10.1136/bmj.e846

The MATISSE study: a randomised trial of group art therapy for people with schizophrenia.

Crawford MJ, Killaspy H, Kalaitzaki E, Barrett B, Byford S, Patterson S, Soteriou T, O'Neill FA, Clayton K, Maratos A, Barnes TR, Osborn D, Johnson T, King M, Tyrer P, Waller D.

2010-08-2714 citations

10.1186/1471-244x-10-65

Interventions

The trial has three arms. As well as the intervention group (group art therapy) there are two other arms: attention control and treatment as usual. The attention control includes activity groups whic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All those treated by secondary mental health services in the four study centres who are aged over 18 years and have a clinical diagnosis of schizophrenia, confirmed by an examination of case notes using operationalised criteria (OPCRIT), will be eligible to take part in the study

Exclusion criteria

Exclusion criteria: 1. Patients who are unwilling to provide written informed consent 2. Patients who speak insufficient English and are not able to complete baseline assessment 3. Have severe cognitive impairment 4. Are already receiving art therapy or any other art therapies (music therapy, drama therapy, or dance/ movement therapy)

Design outcomes

Primary

Measure	Time frame
Global functioning assessed using the Global Assessment of Functioning Scale	—

Secondary

Measure	Time frame
1. Symptoms assessed using the Positive and Negative Syndrome Scale 2. Medication concordance will be assessed using the Morisky Scale 3. Quality of life will be assessed using Euroqol EQ-5D 4. Service costs will be assessed using the Client Service Receipt Inventory 5. Social function using the Social Function Schedule 6. Wellbeing will be assessed using the Psychological General Well Being Index 7. Satisfaction with services will be assessed using the Client Satisfaction Questionnaire 8. Engagement with services will be assessed using the Service Engagement Scale 9. Occupational and housing status 10. Adverse events	—

Measure

Time frame

1. Symptoms assessed using the Positive and Negative Syndrome Scale 2. Medication concordance will be assessed using the Morisky Scale 3. Quality of life will be assessed using Euroqol EQ-5D 4. Service costs will be assessed using the Client Service Receipt Inventory 5. Social function using the Social Function Schedule 6. Wellbeing will be assessed using the Psychological General Well Being Index 7. Satisfaction with services will be assessed using the Client Satisfaction Questionnaire 8. Engagement with services will be assessed using the Service Engagement Scale 9. Occupational and housing status 10. Adverse events

—

Countries

United Kingdom

Outcome results

None listed